<DOC>
	<DOCNO>NCT01817075</DOCNO>
	<brief_summary>This randomized phase III trial study chlorhexidine gluconate cleansing see well work compare control cleanse prevent central line associate bloodstream infection acquisition multi-drug resistant organism young patient cancer undergo donor stem cell transplant . Chlorhexidine gluconate may help reduce bloodstream infection bacterial infection associated central line .</brief_summary>
	<brief_title>Chlorhexidine Gluconate Cleansing Preventing Central Line Associated Bloodstream Infection Acquisition Multi-drug Resistant Organisms Younger Patients With Cancer Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether chlorhexidine gluconate ( CHG ) cleanse decrease central line associate bloodstream infection ( CLABSI ) child cancer receive allogeneic hematopoietic cell transplantation ( HCT ) . SECONDARY OBJECTIVES : I . To determine whether CHG cleanse decrease acquisition multi-drug resistant organism ( MDRO : vancomycin resistant enterococci [ VRE ] , methicillin resistant Staphylococcus aureus [ MRSA ] , etc . ) child cancer receive allogeneic HCT . II . To determine whether CHG cleanse child cancer receive allogeneic HCT associate cutaneous bacterial isolates reduce susceptibility CHG. III . To determine whether CHG cleanse decrease positive blood culture child cancer receive allogeneic HCT . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients receive CHG cleanse topical skin wipe daily ( QD ) 90 day . ARM II : Patients receive control cleanse topical skin wipe QD 90 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>TRANSPLANT PATIENTS : patient undergo plan allogeneic transplant ( malignant nonmalignant diagnosis ) ONCOLOGY PATIENTS : patient oncology diagnosis chemotherapy regimen last additional &gt; = 3 month chemotherapy regimen &lt; 3 month proceed transplant ( allogeneic autologous stem cell rescue ) 3month study period Patients undergo allogeneic transplant must , schedule , external tunneled central venous catheter ( CVC ) ( Broviacs , Hickmans , tunnel percutaneously inserted central catheter [ PICCs ] , etc . ) and/or nontunneled percutaneously inserted central catheter ( PICC ) expect remain place additional &gt; = 3 month Patients acute myelogenous leukemia ( AML ) relapse acute lymphoblastic leukemia ( ALL ) receive chemotherapy with/without transplant must , schedule , external tunnel CVC ( Broviacs , Hickmans , tunnel PICCs , etc . ) and/or nontunneled PICC expect remain place additional &gt; = 3 month All oncology patient receive chemotherapy with/without transplant must , schedule , external tunnel CVC ( Broviacs , Hickmans , tunnel PICCs , etc . ) expect remain place additional &gt; = 3 month All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients previous current line infection ineligible 14 day completion antibiotic Patients totally implanted CVCs port ineligible Patients know allergy hypersensitivity CHG ineligible Patients chronic , severe , generalized skin breakdown ( generalized blistering , burn , severe graft versus host disease [ GVHD ] open sore , etc . ) ineligible Patients currently enrol Children 's Oncology Group ( COG ) study ACCL0934 eligible complete infection observation period study Patients schedule receive broadspectrum prophylactic antibacterial therapy ineligible ; patient receive prophylaxis Pneumocystis pneumonia ( PCP ) ( trimethoprim [ TMP ] /sulfamethoxazole [ SMX ] ) encapsulate organism ( penicillin ) eligible Patients receive sorafenib time enrollment schedule receive sorafenib part treatment plan ineligible Patients use prophylactic antimicrobial lock CVC time enrollment schedule receive antimicrobial lock CVC part treatment plan ineligible Patients previously enrol trial ineligible Females pregnant breastfeeding ineligible</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>